Idiopathic pulmonary fibrosis (IPF) is a devastating condition where the lung tissues progressively thickens and turn into scar tissues leading to breathlessness and ultimately respiratory failure and death. The treatment for IPF has changed drastically over the past few years. Traditionally, IPF were treated with high doses of corticosteroids in combination with other medications to suppress the immune system. New medications, pirfenidone and nintedanib, have made it possible to slow down the progression of the condition. Other supplemental agents such as N-acetylcysteine (NAC) has often been used as an adjunct therapy in pulmonary fibrosis. We often get asked about what the effectiveness of different therapies in pulmonary fibrosis.
Our research pharmacists performed a review of the most recent research evidence in the effectiveness of the different treatments for pulmonary fibrosis. What we found was when all the research data on the different therapies are complied together and compared against each other, pirfenidone and nintedanib are the 2 most effective therapies for the treatment of pulmonary fibrosis.
A 2016 research paper combined the data from 10 research papers that involved the use of pirfenidone, nintedanib, and NAC. The results showed that both pirfenidone and nintedanib, but not NAC, were significantly effective in reducing FVC decline and the risk of FVC ≥10% decline in IPF patients over 12 months. (click here to read the paper)
Another 2016 research combined data from a total of 19 research trials (5,694 patients) comparing 10 different interventions with placebo and an average follow-up period of 1 year. Their analysis suggested that nintedanib, pirfenidone, and sildenafil are the three treatments with the highest probability of reducing mortality in IPF. Indirect comparison showed no significant difference in mortality between pirfenidone and nintedanib.
A 2015 research that combined data from 11 studies included involving pirfenidone, nintedanib and NAC showed that only two treatments, pirfenidone (odds ratio 0.62, 95% credible interval 0.52, 0.74) and nintedanib (0.41, 95% credible interval 0.34, 0.51) produced a statistically significant slowing in the rate of forced vital capacity decline compared with placebo.
Based on our review of the most recent research evidence, our opinion remains the same, that pirfenidone and nintedanib are the only 2 scientifically proven medications to slow down the progression of pulmonary fibrosis and all patients with IPF should be taking one of these medications. For this reason we have been providing affordable and reliable access to pirfenidone for IPF patients for many years, long before its belated approval by the FDA in 2014. For any questions regarding pulmonary fibrosis or how to buy pirfenidone from us, please do not hesitate to contact our pharmacists toll free at 1-888-488-9965. You do not need to be buying pirfenidone to call, our pharmacists are happy to consult on your condition and answer any question absolutely free of any charge or obligations.